Gynecologic Cancer Publications

Gynecologic Cancer

In the trenches: pelvic tuberculosis mimicking advanced stage epithelial ovarian cancer. Elmore RG, Li AJ. Obstet Gynecol 2007; 110: 1417-19.
 

Androgen receptor modulation of EGFR signaling in epithelial ovarian cancer. Li AJ, Scoles DR, Armstrong K, Karlan BY. Gynecologic Oncology 2008; 109: 220-5.

Impact of Statin Therapy on Survival in Epithelial Ovarian Cancer. Elmore RG, Ioffe Y, Scoles DR, Karlan BY, Li AJ. Gynecologic Oncology; in press.

Effect of obesity on survival in epithelial ovarian cancer. J. Pavelka, R. S. Brown, Karlan BY, Cass I, Leuchter RS, Lagasse L, Li AJ Cancer 2006, 207(7):1520-4.

Tertiary cytoreductive Surgery in Recurrent Ovarian Cancer: Selectrion Criteria and Survival Outcome. Karam AK, Santillan A, Bristow RE, Giuntoli RL, Gardner GJ, Cass I, Karlan BY, Li AJGynecol Oncol 2006; in press.

Computed Tomography Of Predictors of Suboptimal Primary Cytoreduction in Patients With Advanced Ovarian Cancer: A Multi-Institutional Reciprocal Validation Study. Axtell, AE, Lee MH, Bristow RE, Dowdy SC, Cliby WA, Raman S, Weaver JP, Gabbay M, Ngo M, Lentz S, Cass I, Li AJ, Karlan BY, Holschneider CH. J Clin Oncol 2006; in press.

Secondary cytoreductive surgery for isolated nodal recurrence in patients with epithelial ovarian cancer. Santallan A, Karam AK, Li AJ Giuntoli RL, Gardner GJ, Cass I, Karlan BY , Bristow Re.Gynecol Oncol 2006. In press.

The prognostic significance of thrombocytosis in uterine papillary serous carcinomas. Lerner D, Walsh C, Cass I, Karlan BY, Li AJ Gynecol Oncol, in press; 2006.

Swisher EM, Sakai W, Karlan BY, Wurz K, Urban, Taniguchi T. Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Research 68:2581-6, 2008.

Li AJ, Scoles DR, Armstrong KU, Karlan BY. Androgen receptor cytosine-adenine-guanine repeat polymorphisms modulate EGFR signaling in epithelial ovarian carcinomas. Gynecol Oncol. 2008 May; 109(2):220-5.

Walsh CS, Ogawa S, Karahashi H, Scoles DR, Pavelka JC, Tran H, Miller CW, Kawamata N, Ginther C, Dering J, Sanada M, Nannya Y, Slamon DJ, Koeffler HP, Karlan BY. ERCC5 is a novel biomarker of ovarian cancer prognosis. J Clin Oncol. 2008;26(18):2952-8.

Fejzo MS, Dering J, Ginther C, Anderson L, Ramos L, Walsh C, Karlan B, Slamon DJ. Comprehensive analysis of 20q13 genes in ovarian cancer identifies ADRM1 as amplification target. Genes Chromosomes Cancer. 2008;47(10):873-83.

Elmore RG, Ioffe Y, Scoles DR, Karlan BY, Li AJ. Impact of statin therapy on survival in epithelial ovarian cancer. Gynecol Oncol; 2008, in press.

Walsh C, Karlan BY, et al. Lymphadenectomy's role in early endometrial cancer: prognostic or therapeutic? JNCI, 2008, in press.

Cass I, Holschneider C, Madden A, Leuchter RS, Lagasse LD, Berek JS, Karlan BY. Prognostic value of second look surgery in optimally cytoreduced ovarian cancer patients. Submitted.

Scoles DR, Pavelka J, Xu X, Karahashi H, Tran H, Armstrong K, Zhang L, Karlan BY. Targeting eIF3c to enhance chemosensitivity of ovarian cancers. PLoS ONE. Submitted.

Pavelka J, Scoles D, Tran H, Armstrong K, Karlan B. Inhibitors of AKT and mTOR pathways enhance platinum sensitivity of cultured ovarian carcinoma cells. Gynecologic Oncology. Submitted.

Li AJ, Scoles DR, Armstrong K, Karlan BY. Androgen receptor modulation of EGFR signaling in epithelial ovarian cancer. Gynecologic Oncology 2008; 109:220-5.

Li AJ, Karlan BY. Androgens and epithelial ovarian cancer: what's the connection? Cancer Biology and Therapy 2008; in press.

Gibbs RS, Karlan BY, Haney A, Nygaard I (eds): Danforth's 10th Edition Obstetrics and Gynecology. Lippincott Williams and Wilkins, Philadelphia, PA, 2008.

Lang J, Karlan BY. Cancer screening - Colorectal cancer. In: 5-minute Ob/Gyn Consult. Hilard PJ, Hillard PJ (eds.) Lippincott, Williams and Wilkins, Philadelphia, PA, 2008.

Lang J, Karlan BY. Screening and well-woman care - ACOG guidelines. In: 5-minute Ob/Gyn Consult. Hilard PJ, Hillard PJ (eds.) Lippincott, Williams and Wilkins, Philadelphia, PA, 2008.

Cass I, Karlan BY. Ovarian and Tubal Cancers. In: Gibbs RS, Karlan BY, Haney A, Nygaard I (eds): Danforth's 10th Edition Obstetrics and Gynecology. Lippincott Williams and Wilkins, Philadelphia, PA, 2008.

Cass I. Ovarian Cancer Screening. Hereditary Gynecologic Cancer: Risk, Prevention and Management. Submitted.

Li AJ. Gestational trophoblastic neoplasms. In: Gibbs RS, Karlan BY, Haney A, Nygaard I (eds): Danforth's Obstetrics and Gynecology, 10th edition. Chapter 63, pages 1073-85. Lippincott Williams and Wilkins, 2008.

Moore K, Moxley KM, Fader AN, Axtell AE, Rocconi RP, Abaid LN, Cass I, Rose PG, Leath, III CA, Rutledge T, Blankenship D, Gold MA. Serous Fallopian Tube Carcinoma: A Retrospective, Multi-institutional Case Control Comparison to Serous Adenocarcinoma of the Ovary. Submitted.

Axtell AE, Cass I, Bristow RE, Chi DS, D. McMeekin S, Moore K, Carson LF, Chura JC, Cliby WA, De Geest K, Muto MG, Belinson JL, Holschneider CH. Benchmarking for quality assurance of surgical cytoreduction in advanced ovarian cancer: multi-institutional; assessment of feasibility and morbidity. Submitted.

Sakai W, Swisher EM, Karlan BY, Agarwal MK, Higgins J, Friedman C, Villegas E, Jacquemont C, Farrugia DJ, Couch FJ, Urban N, Taniguchi T. Secondary mutations as a mechanism of acquired cisplatin resistance in BRCA2-mutated cancers. Nature 451:1116-20, 2008.